Alzheimer's Treatment Costs in China: Building a Budget for Assessment, Medicines, and Care

There is no single national total price for treating Alzheimer's disease in China. A diagnostic review, symptom medication, anti-amyloid treatment, and continuing personal care involve different services and time periods. The price of one vial or a hospital health-screening package cannot establish what an international patient will spend on a complete care plan.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A diagnostic review usually considers history, cognition, daily function, imaging, and indicated laboratory investigations. Further confirmation of amyloid pathology depends on the clinical question and potential treatment. Travelling to China is not itself a reason to order PET, lumbar puncture, every blood biomarker, and a broad genetic panel together. DETeCD-ADRD diagnostic guideline
China's 2025 Commercial Health Insurance Innovative Drug Catalogue lists donanemab injection and lecanemab injection, with those entries effective from January 1, 2026 through December 31, 2027. The accompanying National Healthcare Security Administration notice states that drugs in this catalogue are not paid for by the basic medical insurance fund. The catalogue is intended for reference by commercial insurers and other supplementary arrangements. Official catalogue, NHSA implementation notice
Accompaniment, transport, home safety, hearing or vision support, personal care, and treatment of other conditions can affect whether the patient can continue living in a familiar setting. Choosing an antibody should not erase these needs. If an antibody is unsuitable or unaffordable, symptom management and supportive care remain meaningful options to discuss.

Quick answer

Full guide

As of September 2026, no current written quotation for a specified patient, hospital, and regimen has been obtained for this article. Unverified renminbi totals are therefore not supplied. A useful budget begins by identifying the necessary services and decisions still awaiting clinical assessment; the hospital and pharmacy can then supply actual prices. An unquoted item is neither free nor automatically required.

Identify the pathway before calculating a total

A diagnostic review usually considers history, cognition, daily function, imaging, and indicated laboratory investigations. Further confirmation of amyloid pathology depends on the clinical question and potential treatment. Travelling to China is not itself a reason to order PET, lumbar puncture, every blood biomarker, and a broad genetic panel together. DETeCD-ADRD diagnostic guideline

Symptom medication requires a prescription-specific budget based on ingredient, strength, and formulation. An antibody pathway also involves eligibility assessment, administration, safety imaging, and continuing reviews. The treatments do not have identical purposes. Comparing only monthly medicine prices cannot establish that the more expensive option suits everyone or that the lower-cost option provides the same effect. NIA treatment overview

Request a quotation that can be checked line by line

The following categories are a framework for asking a hospital about charges, not a mandatory package. Remove investigations the clinician does not recommend. Where suitable records already exist, ask whether they can be reviewed before repeating the work.

Budget category	Information needed	Price status
Assessment	Clinic type, cognitive testing, record review, interpretation services	Current RMB quotation required
Diagnostic and eligibility tests	MRI, indicated laboratory tests, and selected PET or CSF testing	Depends on the clinical plan
Medicines	Ingredient, strength, formulation, quantity, initial and later dosing	Pharmacy confirmation required
Administration	Outpatient or inpatient setting, infusion, observation, supplies, nursing	Itemize by service arrangement
Monitoring	Planned imaging, clinician interpretation, functional review	Total against the actual calendar
Unplanned medical care	Additional visits, imaging, or complication management	Cannot be determined in advance
Living and care costs	Accommodation, transport, accompaniment, personal care, care after return	Separate household budget

A quotation should identify its date, validity, and setting of care. General outpatient services and international medical services may have different arrangements. A shared hospital name does not establish identical charges. Before comparing totals from two centers, check that both include the same services; a shorter list can create the appearance of a lower price without covering the same pathway.

One vial price is insufficient for intravenous lecanemab

Intravenous lecanemab involves weight-related dosing, available vial sizes, and an administration schedule. The pharmacy should explain the number of vials required, treatment of unused quantities, and billing practice. Dividing the prescribed milligrams by a package size does not prove that a fractional number of vials will be charged.

The July 2026 US label also distinguishes starting and maintenance arrangements. A budget for care in China must use the actual plan confirmed by the Chinese prescriber under applicable local labeling. Families should not choose a cheaper frequency themselves from an overseas document. Calculate the initial period, later maintenance, and the cost of one visit to China separately instead of multiplying one stage into an assumed lifetime bill. Current US Leqembi label

The September 2026 announcement of Chinese approval for subcutaneous initiation does not establish its local selling price, immediate stock, or a lower total cost than intravenous care. Changing the administration setting can still involve product procurement, training, and monitoring. Revise the budget once the actual product and workable plan are confirmed. Chinese subcutaneous approval announcement

Donanemab costs depend on the dosing and stopping pathway

The current cited US Kisunla label uses an updated dose-escalation schedule and permits consideration of stopping based on amyloid PET findings. A table calculated with an older schedule, or an assumption of indefinite maximum-dose treatment for everyone, may not match the care being proposed. The treating team should confirm the applicable Chinese regimen. Kisunla label

Follow-up PET can add an expense while also contributing to a continuation decision. It should not be treated as an arbitrary optional extra, nor advertised as a guaranteed way for every patient to stop sooner and save a fixed sum. Ask the hospital to explain the relationship between a proposed test and the decision it supports.

Safety-related interruptions can change both attendance and costs. A delayed dose does not necessarily remove the need for clinical review, while an additional MRI may be necessary outside the original calendar. A quotation should distinguish planned services from expenses that depend on events rather than hide both in an unexplained package allowance.

The commercial insurance catalogue is not basic medical insurance reimbursement

China's 2025 Commercial Health Insurance Innovative Drug Catalogue lists donanemab injection and lecanemab injection, with those entries effective from January 1, 2026 through December 31, 2027. The accompanying National Healthcare Security Administration notice states that drugs in this catalogue are not paid for by the basic medical insurance fund. The catalogue is intended for reference by commercial insurers and other supplementary arrangements. Official catalogue, NHSA implementation notice

Catalogue inclusion therefore does not mean every patient is reimbursed. An application, formal review, or negotiation reported during 2026 does not establish that a new payment arrangement has taken effect. Ask the administrator to identify the actual policy or contract applying to the named medicine and date of treatment.

For an international patient, check existing-condition rules, planned treatment abroad, the hospital department, indication, preauthorization, deductible, and limits with the insurer. Having a policy, qualifying for a benefit, and having access to direct billing are different matters. A hospital's relationship with an insurance company is not a promise that this antibody treatment is covered.

Direct billing still requires confirmation for the actual care

Peking Union Medical College Hospital's official international patient guide describes access to commercial insurance direct-billing services and related processes. It is an appropriate starting point for checking that hospital's arrangements, not evidence that every policy will pay. Other hospitals should be checked through their own official channels. PUMCH international patient guide

Ask whether the medicine, diagnostic PET, monitoring MRI, outpatient administration, and inpatient services need separate authorization. If approval is issued, retain its amount and expiry date. A telephone assurance that treatment “should be covered” is less useful than an answer identifying the approved services. For reimbursement after self-payment, establish requirements for invoices, itemized charges, prescriptions, clinical notes, and any translations.

The budget should also show cash-flow requirements. A benefit paid after a claim does not fund a deposit due before care. Confirm the hospital's payment instructions and the insurer's process independently, especially when a third-party coordinator is involved. Any coordination fee should be distinguishable from the hospital's clinical charges.

Old sodium oligomannate prices and reimbursement claims need updating

Sodium oligomannate has a history of Chinese approval and insurance listing. However, Fosun Pharma's December 2025 regulatory disclosure reported that its conditional registration had expired in November 2024 and commercial production and sales were suspended. Resumption depended on further clinical and regulatory requirements. An old webpage displaying a selling price cannot establish lawful, continuing supply today. December 2025 regulatory disclosure

The official list of medicines removed during the 2025 basic insurance catalogue adjustment also includes sodium oligomannate. The related transition payment period ended in June 2026. A September 2026 budget should not continue presenting it as routinely reimbursed under the former policy. Claims of resumed marketing or new reimbursement require newer formal evidence, rather than inference from research or corporate announcements. NHSA removal list

Economic models are not personal hospital quotations

A 2026 Chinese cost-utility study evaluated the antibodies using a model, a societal perspective, and pricing inputs from several regions. Such work informs discussion about resource allocation and payment. Its assumptions about patients, duration, care costs, and administration may differ from an individual's situation. Some modeled costs may not represent bills paid directly to a hospital. 2026 cost-utility analysis

Check the year of the inputs and the treatment scenarios, particularly when prescribing schedules have since changed. An MRI price used in a paper is not a nationwide international-patient tariff. Equally, a population-level economic conclusion cannot decide the value of care for a particular household without considering clinical suitability, preferences, and available resources.

This is why a plausible-looking annual figure should not be copied into a patient proposal merely because it appears in a publication. A transparent estimate explains its assumptions and can be recalculated when a prescription, number of visits, or payment decision changes.

Preserve a budget for continuing care

Accompaniment, transport, home safety, hearing or vision support, personal care, and treatment of other conditions can affect whether the patient can continue living in a familiar setting. Choosing an antibody should not erase these needs. If an antibody is unsuitable or unaffordable, symptom management and supportive care remain meaningful options to discuss.

Ask for a baseline assessment and care budget, then a separate addition for antibody treatment if eligibility is established. Distinguish recurring costs from possible extra services. Record all medical prices in renminbi, enter only confirmed insurance contributions, and list currency-conversion or cross-border payment costs separately. This produces a budget that can change with the findings while making the next decision understandable. NIA cognitive impairment care guidance